The 2021 WHO classification defines GBM as lacking IDH mutation, along with alterations related to telomerase reverse transcriptase (TERT) promoter mutation, epidermal growth factor receptor (EGFR) amplification, chromosome 10 copy number loss, and chromosome 7 copy number gain (Louis et al., 2021). Here, EGFR is linked to glioblastoma.